{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:10:51Z","timestamp":1793034651129,"version":"4.5.0"},"publisher-location":"Chichester, UK","reference-count":72,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd011230.pub2","type":"reference-entry","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T10:48:12Z","timestamp":1410778092000},"source":"Crossref","is-referenced-by-count":34,"title":["Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration"],"prefix":"10.1002","author":[{"given":"Lorenzo","family":"Moja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koren H","family":"Kwag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Bertele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Campomori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Dickersin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon","family":"Loke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mugelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"M\u00fchlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"P\u00fcntmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schmucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju L","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,15]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD011230.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0301-4738.81023","article-title":"Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration","volume":"59","author":"Biswas","year":"2011","journal-title":"Indian Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD011230.pub2-BIB2|cit2","first-page":"ARVO E-Abstract","article-title":"Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. BRAMD","volume":"55","author":"Schauwvlieghe","year":"2014","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"7","key":"10.1002\/14651858.CD011230.pub2-BIB3|cit3","first-page":"1388","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD011230.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD011230.pub2-BIB5|cit5","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"issue":"9900","key":"10.1002\/14651858.CD011230.pub2-BIB6|cit6","first-page":"1258","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD011230.pub2-BIB7|cit7","first-page":"1399","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD011230.pub2-BIB8|cit8","unstructured":"Berg K Lucentis compared to Avastin Study (LUCAS). AAO Annual Meeting, 2013 subspecialty day conference-cast.com\/AAO\/common\/sessions.aspx\/4\/7"},{"issue":"3","key":"10.1002\/14651858.CD011230.pub2-BIB9|cit9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","article-title":"A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"British Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD011230.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/eye.2010.147","article-title":"Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial","volume":"24","author":"Subramanian","year":"2010","journal-title":"Eye"},{"key":"10.1002\/14651858.CD011230.pub2-BIB11|cit11","unstructured":"NCT00559715 Prevention of vision loss in patients with age-related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting clinicaltrials.gov\/show\/NCT00559715"},{"issue":"2","key":"10.1002\/14651858.CD011230.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"e57132","DOI":"10.1371\/journal.pone.0057132","article-title":"Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers","volume":"8","author":"Akl","year":"2013","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD011230.pub2-BIB13|cit13","unstructured":"Avery RL Castellarin AA Steinle NC Dhoot DS Pieramici DJ See R Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD British Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD011230.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/0962280211432211","article-title":"Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it?","volume":"22","author":"Bassler","year":"2013","journal-title":"Statistical Methods in Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD011230.pub2-BIB15|cit15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jclinepi.2009.03.001","article-title":"A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies","volume":"63","author":"Bosco","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD011230.pub2-BIB16|cit16","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007325.pub3","article-title":"Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion","author":"Braithwaite","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011230.pub2-BIB17|cit17","doi-asserted-by":"crossref","first-page":"e4203","DOI":"10.1136\/bmj.e4203","article-title":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD011230.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"issue":"9900","key":"10.1002\/14651858.CD011230.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD011230.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-200868080-00002","article-title":"Neovascular age-related macular degeneration: potential therapies","volume":"68","author":"Chappelow","year":"2008","journal-title":"Drugs"},{"issue":"5","key":"10.1002\/14651858.CD011230.pub2-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdr432","article-title":"Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis","volume":"23","author":"Cortes","year":"2012","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011230.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000355569","article-title":"Cardiac issues of noncardiac drugs: the rising story of avastin in age-related macular degeneration","volume":"231","author":"Cruess","year":"2014","journal-title":"Ophthalmologica"},{"issue":"10","key":"10.1002\/14651858.CD011230.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD011230.pub2-BIB24|cit24","unstructured":"electronic Medicines Compendium (eMC) Avastin 25mg\/ml concentrate for solution for infusion www.medicines.org.uk\/emc\/medicine\/15748"},{"key":"10.1002\/14651858.CD011230.pub2-BIB25|cit25","unstructured":"Esarey J Danneman N A quantitative method for substantive robustness assessment jee3.web.rice.edu\/riskstats.pdf"},{"issue":"8","key":"10.1002\/14651858.CD011230.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"issue":"11","key":"10.1002\/14651858.CD011230.pub2-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Archives of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD011230.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/IAE.0b013e31821dc66f","article-title":"Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study","volume":"31","author":"French","year":"2011","journal-title":"Retina"},{"issue":"10","key":"10.1002\/14651858.CD011230.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0161-6420(93)31466-1","article-title":"Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture","volume":"100","author":"Green","year":"1993","journal-title":"Ophthalmology"},{"issue":"7650","key":"10.1002\/14651858.CD011230.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011230.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"12","key":"10.1002\/14651858.CD011230.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD011230.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD011230.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"The Lancet. Oncology."},{"issue":"7414","key":"10.1002\/14651858.CD011230.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011230.pub2-BIB36|cit36","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available at www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011230.pub2-BIB37|cit37","unstructured":"Horsley W. NHS North East Treatment Advisory Group Bevacizumab (Avastin\u00ae)in the management of neovascular age-related macular degeneration www.netag.nhs.uk\/files\/appraisal-reports\/Bevacizumab%20-Avastin-%20AMD%20-%20NETAG%20appraisal%20report%20-July%202011.pdf"},{"key":"10.1002\/14651858.CD011230.pub2-BIB38|cit38","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Introductory guide MedDRA version 17.0 www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_17_0_english.pdf"},{"issue":"10","key":"10.1002\/14651858.CD011230.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0895-4356(97)00149-2","article-title":"The impact of high-risk patients on the results of clinical trials","volume":"50","author":"Ioannidis","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD011230.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jclinepi.2004.10.019","article-title":"Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials","volume":"58","author":"Ioannidis","year":"2005","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD011230.pub2-BIB41|cit41","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/jama.294.2.218","article-title":"Contradicted and initially stronger effects in highly cited clinical research","volume":"294","author":"Ioannidis","year":"2005","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD011230.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jama.2014.1361","article-title":"Prevalence, characteristics, and publication of discontinued randomized trials","volume":"311","author":"Kasenda","year":"2014","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011230.pub2-BIB43|cit43","first-page":"2803","article-title":"FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye","volume":"15","author":"Kim","year":"2009","journal-title":"Molecular Vision"},{"issue":"4","key":"10.1002\/14651858.CD011230.pub2-BIB44|cit44","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ajo.2008.05.036","article-title":"Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans","volume":"146","author":"Krohne","year":"2008","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD011230.pub2-BIB45|cit45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJM199708213370806","article-title":"Discrepancies between meta-analyses and subsequent large randomized, controlled trials","volume":"337","author":"LeLorier","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD011230.pub2-BIB46|cit46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ajo.2011.05.040","article-title":"Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned?","volume":"152","author":"Lim","year":"2011","journal-title":"American Journal of Ophthalmology"},{"issue":"9827","key":"10.1002\/14651858.CD011230.pub2-BIB47|cit47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD011230.pub2-BIB48|cit48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","article-title":"Testing intravitreal toxicity of bevacizumab (Avastin)","volume":"26","author":"Manzano","year":"2006","journal-title":"Retina"},{"key":"10.1002\/14651858.CD011230.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"g3058","DOI":"10.1136\/bmj.g3058","article-title":"Non-publication and delayed publication of randomized trials on vaccines: survey","volume":"348","author":"Manzoli","year":"2014","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD011230.pub2-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD011230.pub2-BIB51|cit51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/eye.2011.66","article-title":"Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab","volume":"25","author":"Meyer","year":"2011","journal-title":"Eye"},{"issue":"1","key":"10.1002\/14651858.CD011230.pub2-BIB52|cit52","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","article-title":"Vascular endothelial growth factor a in intraocular vascular disease","volume":"120","author":"Miller","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD011230.pub2-BIB53|cit53","volume-title":"Cancer Therapeutics Evaluation Program. Common Toxicity Criteria for Adverse Events","year":"2003"},{"issue":"5","key":"10.1002\/14651858.CD011230.pub2-BIB54|cit54","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1136\/bjophthalmol-2011-301109","article-title":"The estimated prevalence and incidence of late stage age related macular degeneration in the UK","volume":"96","author":"Owen","year":"2012","journal-title":"British Journal of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD011230.pub2-BIB55|cit55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011230.pub2-BIB56|cit56","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD011230.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2307\/2531052","article-title":"Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models","volume":"42","author":"Robins","year":"1986","journal-title":"Biometrics"},{"issue":"4","key":"10.1002\/14651858.CD011230.pub2-BIB58|cit58","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/14740338.5.4.553","article-title":"Incidence and management of bevacizumab-related toxicities in colorectal cancer","volume":"5","author":"Saif","year":"2006","journal-title":"Expert Opinion on Drug Safety"},{"issue":"3","key":"10.1002\/14651858.CD011230.pub2-BIB59|cit59","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Statistical Methods in Medical Research"},{"issue":"3","key":"10.1002\/14651858.CD011230.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/ICU.0b013e3283386783","article-title":"Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review","volume":"21","author":"Schmucker","year":"2010","journal-title":"Current Opinion in Ophthalmology"},{"key":"10.1002\/14651858.CD011230.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"e42701","DOI":"10.1371\/journal.pone.0042701","article-title":"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard","volume":"7","author":"Schmucker","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1002\/14651858.CD011230.pub2-BIB62|cit62","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","volume":"181","author":"Singh","year":"2009","journal-title":"CMAJ"},{"issue":"8","key":"10.1002\/14651858.CD011230.pub2-BIB63|cit63","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005139.pub3","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","author":"Solomon","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011230.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1755-3768.2009.01669.x","article-title":"Descending doses of intravitreal bevacizumab for the regression of diabetic neovascularization","volume":"89","author":"Stergiou","year":"2011","journal-title":"Acta Ophthalmologica"},{"key":"10.1002\/14651858.CD011230.pub2-BIB65|cit65","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention . Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available at www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011230.pub2-BIB66|cit66","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monocolonal antibodies: a systematic review and meta-analysis","author":"Thulliez","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD011230.pub2-BIB67|cit67","first-page":"1","article-title":"Assessing the influence of a single study in the meta-analysis estimate","volume":"8","author":"Tobias","year":"1999","journal-title":"Stata Technical Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD011230.pub2-BIB68|cit68","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macula degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Global Health"},{"issue":"8","key":"10.1002\/14651858.CD011230.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD011230.pub2-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1167\/iovs.12-10260","article-title":"Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach","volume":"54","author":"Xu","year":"2013","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD011230.pub2-BIB71|cit71","first-page":"355","article-title":"Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2014","journal-title":"International Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD011230.pub2-BIB72|cit72","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011230.pub2","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","author":"Moja","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:38:33Z","timestamp":1625042313000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD011230.pub2"}},"subtitle":[],"editor":[{"given":"Lorenzo","family":"Moja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,9,15]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011230.pub2","relation":{},"subject":[],"published":{"date-parts":[[2014,9,15]]}}}